Furthermore, patients were includedin a high-volume, dedicated multicentre prostate cancer network with a prospectively maintained database and analysed by nuclear medicine physicians with ample experience in PSMA PET reading according to E-PSMA guidelines [14]. This evidence concerns the gene FOLH1 and prostate cancer.